Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Multiple sclerosis drugs: sticker shock.

Hauser SL, Johnston SC.

Ann Neurol. 2012 May;71(5):A5-6. doi: 10.1002/ana.23608. No abstract available.

PMID:
22522488
2.

Therapeutic advances: beta-interferon for multiple sclerosis.

Clark W.

J Clin Pharm Ther. 1996 Aug;21(4):195-9. Review.

PMID:
8933292
3.

Sticker shock waves: Players to respond to drug priciness.

Wehrwein P.

Manag Care. 2015 Dec;24(12):34. No abstract available.

4.

Absenteeism and health-benefit costs among employees with MS.

Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK.

Curr Med Res Opin. 2009 Jun;25(6):1469-76. doi: 10.1185/03007990902905468.

PMID:
19422277
5.

Hu23F2G. 23F2G, LeukArrest.

[No authors listed]

Drugs R D. 1999 Jan;1(1):25-6. No abstract available.

PMID:
10565976
6.

Advancement of therapies for neuroprotection in multiple sclerosis.

Lo A.

Expert Rev Neurother. 2008 Sep;8(9):1355-66. doi: 10.1586/14737175.8.9.1355. Review.

PMID:
18759548
7.

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS.

Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J.

Neurology. 1998 Aug;51(2):529-34.

PMID:
9710030
8.

Approaches to neuroprotective strategies in multiple sclerosis.

Tselis A, Khan OA, Lisak RP.

Expert Opin Pharmacother. 2010 Dec;11(17):2869-78. doi: 10.1517/14656566.2010.508070. Epub 2010 Aug 5. Review.

PMID:
20687779
9.

Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies.

van Noort JM, van den Elsen PJ, van Horssen J, Geurts JJ, van der Valk P, Amor S.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):68-81. Review.

PMID:
21143143
10.

[Social and economic impact of multiple sclerosis].

Béneton C, Rumbach L.

Rev Prat. 1999 Nov 1;49(17):1890-3. French.

PMID:
10598506
11.

Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies?

Stys PK.

Ann Neurol. 2004 May;55(5):601-3. No abstract available.

PMID:
15122698
12.

Recession has not affected access to prescription drugs in US.

Roehr B.

BMJ. 2011 Dec 20;343:d8242. doi: 10.1136/bmj.d8242. No abstract available.

PMID:
22187196
13.

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H.

J Neuroimmunol. 2000 Jul 24;107(2):161-6. Review.

PMID:
10854651
14.

Combination therapy in multiple sclerosis.

Fernández O.

J Neurol Sci. 2007 Aug 15;259(1-2):95-103. Epub 2007 May 15. Review.

PMID:
17507031
15.

Glatiramer in the treatment of multiple sclerosis.

Rizvi SA, Kim E, Moodie J.

Int J Nanomedicine. 2006;1(3):283-9. Review.

16.

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H.

Ernst Schering Res Found Workshop. 2005;(53):23-38. Review. No abstract available.

PMID:
16315607
17.

Multiple sclerosis and disease-modifying therapies.

Minen MT, Karceski S.

Neurology. 2011 Jul 26;77(4):e26. doi: 10.1212/WNL.0b013e318229e6ca. No abstract available.

PMID:
21788616
18.

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Lopez-Diego RS, Weiner HL.

Nat Rev Drug Discov. 2008 Nov;7(11):909-25. doi: 10.1038/nrd2358. Review.

PMID:
18974749
19.

Endogenous neuroprotection in multiple sclerosis.

Gonsette RE.

Acta Neurol Belg. 2010 Mar;110(1):26-35. Review.

PMID:
20514924
20.

[Early multiple sclerosis therapy in the effects of public health economics].

Rieckmann P.

Med Klin (Munich). 2001 Sep 15;96 Suppl 1:17-21. German.

PMID:
11603111
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk